COX6CP16

Across TCGA pan-cancer cohorts, COX6CP16 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of COX6CP16’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where COX6CP16 RNA is repressed in tumor relative to normal tissue. In most cancer types COX6CP16 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, BRCA, and CHOL are the cancer types where COX6CP16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in COX6CP16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	−0.378	.003	4	view →
BRCA	All	II,III,IV	+0.175	.015	4	view →
CHOL	All	All	−0.586	.004	2	view →
KIRC	All	II,III,IV	−0.031	.029	2	view →
STAD	Male	All	+0.116	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

COX6CP16–LIHC

Open the LIHC breakdown →